1. | dcjl4501 | |
2. | 143sam | |
3. | lodiboomer32 | |
4. | stephenlove7 | |
5. | hankj8247 |
1. | dcjl4501 | |
2. | 143sam | |
3. | lodiboomer32 | |
4. | stephenlove7 | |
5. | hankj8247 |
1. | lodiboomer32 01/30/2018 SeeThruEquity Initiates Coverage on AzurRx BioPharma, Inc. (NASDAQ CM: AZRX) with a Price Target of $10.00 |
2. | 143sam 04/18/2018 AzurRx BioPharma Announces Positive Preclinical Data with AZX1103 |
3. | dcjl4501 01/30/2018 You sure? Up 14% |
4. | dcjl4501 04/23/2018 AzurRx BioPharma and Mayoly-Spindler Announce Additional Positive Interim Data for MS1819-SD Phase II in Exocrine Pancreatic Insufficiency (EPI) |
5. | hankj8247 01/30/2018 SeeThruEquity is chump change |
6. | stephenlove7 02/12/2018 AzurRx BioPharma Announces Enrollment of Three New Patients for its Phase IIa Study of MS1819-SD |
7. | dcjl4501 01/18/2018 AzurRx BioPharma Announces Receipt of Required Approvals to Add French Clinical Site for its Phase IIa Study of MS1819-SD for Exocrine Pancreatic Insufficiency |